207 related articles for article (PubMed ID: 28587731)
1. Prediction of clinical outcome using blood flow volume in the superior mesenteric artery in patients with pseudomyxoma peritonei treated by cytoreductive surgery.
Dohan A; Barral M; Eveno C; Lo Dico R; Kaci R; Pasteur-Rousseau A; Soyer P; Pocard M; Bonnin P
Eur J Surg Oncol; 2017 Oct; 43(10):1932-1938. PubMed ID: 28587731
[TBL] [Abstract][Full Text] [Related]
2. Post-operative wall shear stress in the superior mesenteric artery: Biomarker of long term outcome in patients with residual disease after incomplete cytoreductive surgery for pseudomyxoma peritonei.
Barral M; El Sanharawi I; Eveno C; Dohan A; Launay JM; Lo Dico R; Pocard M; Bonnin P
Eur J Surg Oncol; 2019 Sep; 45(9):1727-1733. PubMed ID: 30871885
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
4. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
Sugarbaker PH
Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
[TBL] [Abstract][Full Text] [Related]
6. Huge pseudomyxoma peritonei: Surgical strategies and procedures to employ to optimize the rate of complete cytoreductive surgery.
Benhaim L; Honoré C; Goéré D; Delhorme JB; Elias D
Eur J Surg Oncol; 2016 Apr; 42(4):552-7. PubMed ID: 26868165
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.
Delhorme JB; Severac F; Averous G; Glehen O; Passot G; Bakrin N; Marchal F; Pocard M; Lo Dico R; Eveno C; Carrere S; Sgarbura O; Quenet F; Ferron G; Goéré D; Brigand C;
Br J Surg; 2018 May; 105(6):668-676. PubMed ID: 29412465
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report.
Thorgersen EB; Melum E; Folseraas T; Larsen SG; Line PD
World J Surg Oncol; 2018 Sep; 16(1):180. PubMed ID: 30185175
[TBL] [Abstract][Full Text] [Related]
10. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery plus perioperative intraperitoneal chemotherapy in pseudomyxoma peritonei: aspects of the learning curve.
Andréasson H; Lorant T; Påhlman L; Graf W; Mahteme H
Eur J Surg Oncol; 2014 Aug; 40(8):930-6. PubMed ID: 24656455
[TBL] [Abstract][Full Text] [Related]
12. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
[TBL] [Abstract][Full Text] [Related]
13. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
[TBL] [Abstract][Full Text] [Related]
15. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
[TBL] [Abstract][Full Text] [Related]
16. The pre-operative neutrophil-lymphocyte ratio predicts overall and disease-free survival following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with pseudomxyoma peritonei of appendiceal origin.
Rangarajan K; Chandrakumaran K; Dayal S; Mohamed F; Moran BJ; Cecil TD
Int J Hyperthermia; 2018 Aug; 34(5):559-563. PubMed ID: 29063804
[TBL] [Abstract][Full Text] [Related]
17. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
Galan A; Rousset P; Mercier F; Képénékian V; Valette PJ; Glehen O; Passot G
Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
[TBL] [Abstract][Full Text] [Related]
18. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
19. [Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
Smeenk RM; Verwaal VJ; Zoetmulder FA
Ned Tijdschr Geneeskd; 2007 Feb; 151(7):418-23. PubMed ID: 17343142
[TBL] [Abstract][Full Text] [Related]
20. [Hyperthermic intraperitoneal chemotherapy combined with cytoreductive procedure in patients with peritoneal pseudomyxoma].
Gafton GI; Senchik KY; Kireeva GS; Petrov VG; Semiglazov VV; Guseynov KD; Bespalov VG; Belyaeva OA; Belyaev AM
Khirurgiia (Mosk); 2016; (5):26-30. PubMed ID: 27271716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
